Hot Deals:
a v thomas 11,770.00 (-0.25 %) adtech 29.00 (-3.33 %) amol minechem 620.00 (1.64 %) anand i-power 20.00 anglo french 370.00 (-2.37 %) aricent 575.00 (0.88 %) arkfin investments 50.00 arohan 181.00 (0.56 %) assam carbon 227.00 (-1.30 %) associated pigments 42.00 (-4.55 %) atlas copco 9,100.00 (1.11 %) auckland international 130.00 (-3.70 %) axles 162.00 (1.25 %) balmer lawrie 300.00 bharat hotels 162.00 (1.25 %) bima mandi 700.00 bira 91 750.00 (-2.85 %) boat 829.00 (-0.12 %) c & s electric 470.00 (-4.08 %) capgemini 12,100.00 (1.68 %) care health 135.00 (3.85 %) carrier aircon 260.00 (1.96 %) cial 180.00 (-1.64 %) csfbl 265.00 (-3.64 %) csk 170.00 (6.25 %) dalmia refract 81.00 (-4.71 %) dsp merrill lynch 1,000.00 east india pharma 44.00 (2.33 %) eaton fluid 380.00 (1.33 %) electronica plastic 4,100.00 (-4.65 %) elgi ultra 400.00 elofic 1,909.00 (0.47 %) esl steel 39.00 (11.43 %) fincare business 43.00 fincare sfbl 74.00 (1.37 %) fino paytech 160.00 (14.29 %) frick india 3,806.00 (0.16 %) gkn drive 1,240.00 (-0.80 %) go digit gil 354.00 (1.14 %) godavari bio 71.00 (1.43 %) hdbfsl 590.00 (-1.67 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,200.00 (-2.61 %) hella india 350.00 (6.06 %) hero fincorp 690.00 (-3.36 %) hicks 2,100.00 (-2.55 %) hira ferro 120.00 (-0.83 %) honeywell electrical 3,555.00 (-1.25 %) icex 5.00 (-0.20 %) incred financial 100.00 india carbon 1,010.00 (1.00 %) india exposition 146.00 (0.69 %) indian potash 1,405.00 (0.36 %) indofil 690.00 (-2.82 %) infinite computer 700.00 inkel 12.95 (-0.38 %) ixigo 97.00 (-2.02 %) jana sfbl 75.00 kial 107.00 (-2.73 %) kurlon enterprise 640.00 (-3.03 %) kurlon limited 426.00 (-3.18 %) lava 127.00 (0.79 %) manipal hfsl 72.50 (0.69 %) manjushree tech 970.00 (-3.10 %) martin & harris 1,500.00 (0.33 %) merino 2,770.00 (0.73 %) minosha 280.00 (-3.45 %) mitsubishi heavy 355.00 (1.43 %) mkcl 415.00 (1.22 %) mobikwik 425.00 (-5.56 %) mohan meakin 1,180.00 (-2.64 %) mohfl 10.75 (-9.66 %) msei 0.98 (-2.00 %) msil 56.00 (3.70 %) nayara energy 152.00 (0.66 %) nayara energy ncd 250.00 ncdex 275.00 ncl buildtek 200.00 (2.56 %) ncl holdings 47.50 (1.06 %) nse 3,100.00 (1.64 %) orbis financial 86.00 (1.18 %) oswal minerals 65.00 (1.56 %) otis 3,700.00 (-2.63 %) oyo rooms 69.00 (-2.82 %) panasonic appliances 293.00 (-4.25 %) panasonic avc 29.10 (0.34 %) paymate india 600.00 (-3.38 %) pharma easy 32.00 (-8.57 %) philips domestic 605.00 (0.83 %) philips india 1,100.00 (1.85 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 490.00 (-2.00 %) rasoi 32,000.00 (3.23 %) reliance gic 340.00 resins plastics 414.00 (1.97 %) ring plus 370.00 (1.37 %) rrl 2,800.00 (-1.75 %) sab miller 303.00 (1.00 %) satya micro 201.00 (0.50 %) scottish assam 500.00 (-3.85 %) shriram life 251.00 (0.40 %) sigachi lab 40.10 (0.25 %) signify 1,100.00 (4.46 %) simpson & company 3,500,000.00 smile micro 52.00 (-1.89 %) sportskeeda 3,303.00 sterlite power 524.00 (0.19 %) studds 950.00 (-0.52 %) svsml 510.00 (-2.30 %) t stanes 675.00 tata capital 56.00 (1.82 %) tata tech 5,400.00 (4.85 %) teesta agro 67.00 (-4.29 %) trl krosaki 1,224.00 (-2.16 %) utkarsh coreinvest 127.00 (-2.31 %) vikram solar 55.50 (-0.89 %) xerox 243.00 (1.25 %)
×

wintac Limited

5.00
+ 0.00 %
Scrip Name
WINTAC
ISIN No.
INE812C01016
PAN No.
AAACR8613H
Face Value
10
No. of Outstanding Shares
10,024,242
Market Capitalization
5.01 Crore

About WINTAC LIMITED Delisted/Unlisted Shares

WINTAC LIMITED was established as an offspring of Bangalore Pharmaceuticals and Research Laboratories Private Limited under the name of RECON LIMITED. In 2001, the name of the company was changed to Wintac Limited. The Company is engaged in the business of manufacturing goods and all its other activities revolve around this business. The company’s range of specialties includes Large and small-volume injectable and Ophthalmic solutions.

The delisting open offer for shares of WINTEC LIMITED was successful as per Regulation 17 of the Delisting Regulations at an exit price of `350 per share under the Reverse Book Building Process. The BSE vide its’ notice no. 20201211-16 dated December 11, 2020, communicated that the trading in the Equity Shares of the Company WINTEC LIMITED   (Scrip Code: 524758) will be discontinued from December 18, 2020, and the scrip will be delisted from Exchange records with effect from December 28, 2020. 

Wintac Limited provides outsourcing for sterile pharmaceutical products and Ophthalmic Solutions. Wintac Limited takes care of its customers from formulation development to commercial manufacturing.

The product range of the company includes a wide range of ophthalmic preparations and Injectables of Large and small volume parenteral.

The equity shares of the company have been delisted from the Bombay Stock Exchange of India on December 28, 2020.

INCORPORATION DETAILS

CIN

L85110KA1990PLC011166

Registration Date

23 August 1990

Category/Sub-category of the Company

Public Limited

Address of the Registered office and contact details

54/1, BOODHIHAL, NELAMANGALA,

BENGALURU - 562123.

PH:- 080-67086500

Name, Address, and Contact Details of

Registrar and Transfer Agent, if any

CANBANK COMPUTER SERVICES LTD.,

NO.218, J.P.ROYALE, II MAIN, SAMPIGE ROAD,

MALLESWARAM, BANGALORE - 560003.

PH: 080-23469661/9662

 PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Name and Description of main products/services

NIC Code of the product/service

% to the total turnover of the Company

Formulation Sales

99532693

80.65%

Manufacturing Charges

99532693

0.21%

Formulation Development

99839390

19.14%

 BOARD OF DIRECTORS

Shri S.T.R. Mady (Chairman)

Shri S. Jayaprakash Mady (Director)

Shri R.A. Thirumoorti (Director)

Dr. K. Paranjothy (Director)

Ms. S. Nanthitha (Additional Director)

Mr. Arshad Kagalwalla (Additional Director)

Shri Sunil B. Gundewar (Manager & C.O.O)

Shri B.P. Thyagaraj V.P. (Finance) & Secretary

PARTICULAR'S OF SUBSIDIARY AND ASSOCIATE COMPANIES

WINTAC LIMITED does not have any subsidiary or associate company.

WINTAC LIMITED DELISTED SHARE DETAILS

 

 

 

 

SHAREHOLDING PATTERN

(As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

VEEGO Pharma LLC (Promoter)

92,40,346

92.18%

2

Public Shareholding

7,83,896

7.82%

 

Total

1,00,24,242

100.00%

INDUSTRY OUTLOOK

 Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment availability has helped India to manufacture pharma products at a very low cost.

The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.

Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.

After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.

 PROFIT & LOSS STATEMENT OF WINTAC LIMITED (In Rs. Lakhs)

PARTICULARS

2020

2019

2018

2017

Revenue from Operations

8,511.01

7,192.01

4,479.70

3,489.81

EBITDA

276.70

337.55

-597.30

-733.59

Finance Cost

191.27

93.38

89.92

99.65

Depreciation

723.76

418.13

354.64

363.18

Other Income

275.97

194.95

71.88

110.50

Profit/Loss before Tax

-362.36

20.99

-969.98

-1,085.91

Exceptional items

0.00

0.00

0.00

118.87

Total Tax

-56.14

10.08

9.24

-121.03

Profit After Tax (PAT) 

-306.22

10.91

-979.22

-846.01

EPS

-3.05

0.11

-9.77

-8.44

BALANCE SHEET OF WINTAC LIMITED (In Rs. Lakhs)

PARTICULARS

31st March 2020

31st March 2019

ASSETS

   

NON CURRENT ASSETS

   

Tangible assets

10,747.66

9,085.09

Intangible assets

48.30

49.30

Financial assets

47.03

441.87

Tax assets (net)

724.91

643.33

Other non-current assets

127.84

195.62

TOTAL NON CURRENT ASSETS

11,695.74

10,415.21

CURRENT ASSETS

   

Inventories

2,532.42

1,944.62

Trade Receivables

309.71

191.82

Cash and cash equivalents

134.93

6.23

Financial assets

100.90

192.53

Other current assets

1,375.68

860.62

TOTAL CURRENT ASSETS

4,453.64

3,195.82

TOTAL ASSETS

16,149.38

13,611.03

EQUITY

   

Share capital

1,002.42

1,002.42

Reserves and surplus

-1,819.26

-1,440.59

TOTAL EQUITY

-816.84

-438.17

NON CURRENT LIABILITIES

   

Borrowings

2,128.15

1,378.31

Other non-current liabilities

9.88

13.19

Long Term Provision

345.42

111.83

TOTAL NON CURRENT LIABILITIES

2,483.45

1,503.33

CURRENT LIABILITIES

   

Short-term borrowings

238.15

5,016.97

Trade payables

1,319.90

1,264.74

Other Current Liabilities

12,844.99

6,148.65

Short Term Provision

79.73

115.51

TOTAL CURRENT LIABILITIES

14,482.77

12,545.87

TOTAL LIABILITIES

16,966.22

14,049.20

TOTAL EQUITY AND LIABILITIES

16,149.38

13,611.03

 DIVIDEND HISTORY

Particulars

2020

2019

2018

Dividend (final + interim) (In Rs.)

Nil

Nil

Nil

Retained Earnings (Consolidated) (In Rs. Lakhs)

-7,328.29

-6,949.62

-6,933.62

 PERFORMANCE OF THE COMPANY

Revenue from Operations of the company increased by 18.34% from Rs. 7,192.01 lakhs in FY 2019 to Rs. 8,511.01 lakhs in FY 2020. The Company earns 85.31% (Previous Year 83.97% from two customers) of revenue from operations has been earned from a single customer.

EBITDA of the company decreased by 18.03% from Rs. 337.55 lakhs in FY 2019 to Rs. 276.70 lakhs in FY 2020. EBITDA margins decreased from 4.69% in FY 2019 to 3.25% in FY 2020.

The company incurred a loss of Rs. 306.22 lakhs in FY 2020, as against a profit of Rs. 10.91 lakhs.

The current ratio of the company as of 31st March 2020 was 0.30.

The company’s net worth is negative and is Rs. -816.84 lakhs. Moreover has a debt of Rs. 2,366.30 lakhs as of 31st March 2020.

The company has not given any dividends for the past three years.

Annual Reports

2020-21

Download

2019-20

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi